What is GOVX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for GOVX?

P/E (TTM) is n/a and 52-week range is $0.28 to $15.75 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s GOVX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for GOVX?

The company profile lists revenue (TTM) near $6M, net income (TTM) near $-2.37B, EPS (TTM) near $-13.92 when available from the market-data feed. Figures are informational and may lag live markets.

Where is GeoVax Labs Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Smyrna, Georgia, US, 7.4M shares outstanding, ISIN US3736787058 when available from company profile and filing metadata.

GeoVax Labs Inc

$GOVX

Health Care · Biotechnology

IR Run Scenarios

$0.28

-1.95%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is headquartered in Smyrna, Georgia and currently employs 19 full-time employees. Its lead clinical program is GEO-CM04S1, a COVID-19 vaccine, which is in three phase II clinical trials, being evaluated as a primary vaccine for immunocompromised patients, such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient; a booster vaccine in patients with chronic lymphocytic leukemia (CLL); and a COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, having completed a multicenter Phase I/II clinical trial for advanced head and neck cancers. The company is developing GEO-MVA, a vaccine targeting Mpox and smallpox. Its other product candidates include GEO-EM01-Z, GEO-EM01-S, GEO-MM01, GEO-ZM02 and others.

Employees

Website

www.geovax.com/

IPO

1994-04-04

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)